An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer.

Sarat Chandarlapaty Maura N Dickler José Alejandro Pérez-Fidalgo Rafael Villanueva-Vázquez Jennifer M Giltnane Mary R Gates Ching-Wei Chang Sravanthi Cheeti Jill Fredrickson Xiaojing Wang Ann Collier Heather M Moore Ciara Metcalfe Jennifer Lauchle Eric W Humke Aditya Bardia

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

GDC-0927 appeared to be well-tolerated with pharmacokinetics supporting once daily dosing. There was evidence of target engagement and preliminary evidence of anti-tumor activity in heavily pretreated patients with advanced/metastatic ER+/HER2- breast cancer with and without ESR1 mutations.

Keyphrases

estrogen receptor
positive breast cancer
squamous cell carcinoma
locally advanced
small cell lung cancer
rectal cancer
neoadjuvant chemotherapy
social media
radiation therapy
physical activity
bone mineral density
open label